Articles

Articles | May 26, 2023
Will ChatGPT Put Data Sharing at Risk?

Large language models (LLMs) have emerged as transformative tools, reshaping the landscape of natural language processing and understanding. Models of this type (such as BERT, LLaMA, and GPT-4) have ...
Articles | May 11, 2023
4 Ways Organizations Can Think About Data Sharing

Here are four micro-stories showcasing how our clients are safely and effectively unlocking value from structured and unstructured data.
Articles | May 5, 2023
7 Effective Ways Providers and Payers Improve Healthcare with Sensitive Data

Here are seven micro-stories showcasing how our clients are safely and effectively unlocking value from structured and unstructured data.
Articles | May 4, 2023
Good Governance for Anonymized Data

Anonymized data can be a valuable resource for advancing research and achieving socially and organizationally beneficial outcomes. Effective and responsible use of anonymized data entails the ...
Articles | May 1, 2023
7 Success Stories: How Health Tech & Analytics Companies Safely Harness Sensitive Data for Innovation

Here are seven micro-stories showcasing how our clients are safely and effectively unlocking value from structured and unstructured data.
Articles | August 4, 2022
Advancing Privacy-Enhancing Technologies

There is a tremendous opportunity to use data safely and responsibility to the benefit of people and society. We see an increasing need for the integration and deployment of suites of tools that are ...
Articles | January 4, 2022
Are You Ready for the EU Clinical Trials Regulation?

Privacy Analytics’ Redaction-as-a-Service ensures fast, cost-effective clinical trial document submissions at scale Reduces submission time from weeks to days using proprietary Mirage software – ...
Articles | October 28, 2020
FPF Privacy and Pandemics Position Statement

We believe that data-driven insights are critical to addressing challenges introduced by the current pandemic, and that benefits can be realized while respecting privacy. What are the challenges ...
Articles | October 28, 2020
How anonymization can enrich every stage of the drug development lifecycle

I wrote in our September newsletter about how trial sponsors are well advised to view transparency as much more than just a box that has to be checked off. This time, I would like to dig deeper into ...
Articles | September 9, 2020
Beyond a box tick

Pharmaceutical companies today are well-advised to view transparency as an opportunity to enhance their reputation in the marketplace and earn trust with stakeholders, which can ultimately benefit ...

Filter by Data Type

Categories